10月22日 - ** Arcturus Therapeutics ARCT.O股价盘前下跌61.8%至8.84美元
** 该公司称，在一项中期研究中，对其实验性囊性纤维化疗法治疗后第1天和第28天的肺功能进行的初步分析表明，治疗效果没有改善。
** 然而，第 42 天的测量结果表明肺功能有所改善
** 粘液堵塞减少的早期信号令人鼓舞 - ARCT
** 实验性吸入式 mRNA 疗法 ARCT-032 总体上安全且耐受性良好 - 联合研究
** 拟于 2026 年上半年在多达 20 名 CF 参与者中启动一项为期 12 周的安全性和初步疗效研究。
** CF是一种遗传性疾病，会导致体内器官积聚粘稠的粘液，主要影响肺部和胰腺
** 截至上次收盘，该公司股价年累计上涨 36.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.